Ozempic Lowers Kidney Disease Risk by 24% in New Study
TL;DR Summary
Novo Nordisk's diabetes drug Ozempic shows promising results in treating chronic kidney disease (CKD), significantly reducing the risk of major kidney and cardiovascular events in high-risk patients. This development could lead to FDA approval for CKD treatment, expanding Ozempic's market and boosting Novo Nordisk's revenue growth.
Topics:health#businesspharmaceuticals#chronic-kidney-disease#fda-approval#novo-nordisk#ozempic#semaglutide
- Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again The Motley Fool
- Now, weight loss drug semaglutide can lower risk of kidney disease by 24 per cent The Indian Express
- Ozempic may help fight kidney disease, study with Orlando researcher finds Orlando Sentinel
- #VisualAbstract: Semaglutide Improves Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease 2 Minute Medicine
- Study finds Ozempic cuts risk of chronic kidney disease complications, Epidurals linked to reduction in serious complications after childbirth, Moroccan Fava Bean Soup WPR
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 5 min read
Condensed
94%
816 → 46 words
Want the full story? Read the original article
Read on The Motley Fool